Reset filter
Trefwoorden
D016430 ×
Meer tonen Trefwoorden
Inhoudsopgave
  1. 1. Klinische studie
  2. 2. Routinedocumentatie
  3. 3. Register-/kohortstudies
  4. 4. Kwaliteitswaarborging
  5. 5. Datastandaard
  6. 6. Patiëntenvragenlijst
  7. 7. Medisch vakgebied
    1. 7.1. Anesthesie
    1. 7.2. Dermatologie
    1. 7.3. HNO
    1. 7.4. Geriatrie
    1. 7.5. Gynaecologie/Ostetrie
    1. 7.6. Interne geneeskunde
      1. Hematologie
      1. Epidemiologie
      1. Cardiologie/Angiologie
      1. Pneumologie
      1. Gastro-enterologie
      1. Nefrologie
      1. Endocrinologie/Metabolisme
      1. Rheumatologie
    1. 7.7. Neurologie
    1. 7.8. Oogheelkunde
    1. 7.9. Palliatieve zorg
    1. 7.10. Pathologie/Forensische Geneeskunde
    1. 7.11. Kindergeneeskunde
    1. 7.12. Psychiatrie/Psychosomatisch
    1. 7.13. Radiologie
    1. 7.14. Chirurgie
      1. Algemene/maag-darm-chirurgie
      1. Neurochirurgie
      1. Plastische chirurgie
      1. Cardiothoracale chirurgie
      1. Traumachirurgie/Orthopedie
      1. Vaatchirurgie
    1. 7.15. Urologie
    1. 7.16. Tandheelkunde/MKG
Geselecteerde datamodellen

U moet ingelogd zijn om meerdere datamodellen te selecteren en die te downloaden of te analyseren.

271 Zoekresultaten.
Relevantie Beoordeling Nieuwe eerst Oude eerst

Eligibility Melanoma NCT02475213

- 08-05-19 - 1 Formulier, 2 Itemgroepen, 17 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Safety Study of MGA271 in Combination With Pembrolizumab in Refractory Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02475213

Eligibility Melanoma NCT02459067

- 08-05-19 - 1 Formulier, 2 Itemgroepen, 29 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
ImmuniCell® in Patients With Advanced Cancers; ODM derived from: https://clinicaltrials.gov/show/NCT02459067

Eligibility Melanoma NCT02381314

- 07-05-19 - 1 Formulier, 2 Itemgroepen, 13 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Safety Study of MGA271 in Combination With Ipilimumab in Refractory Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02381314

Eligibility Melanoma NCT00147550

- 19-10-16 - 1 Formulier, 2 Itemgroepen, 16 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.; ODM derived from: https://clinicaltrials.gov/show/NCT00147550

Eligibility NCT00522834 Melanoma - Eligibility

- 20-09-21 - 1 Formulier, 2 Itemgroepen, 13 Data-elementen, 2 Talen
Itemgroepen: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00522834

Medication Form Melanoma (NCT01274338)

- 20-09-21 - 1 Formulier, 6 Itemgroepen, 35 Data-elementen, 1 Taal
Itemgroepen: Header, On Treatment Reporting Period, OFF TREATMENT, Corticosteroid Medication, Immunosuppressant Medication, Hormonal Replacement Therapy Medication
E1609 Corticosteroid/Immunosuppressant/Hormone Replacement Medication Form Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery NCT01274338 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B1F0BB2E-39FF-B3FA-E040-BB89AD430140

Eligibility DRKS00003621 NCT00518895 Melanoma - Eligibility

- 20-09-21 - 1 Formulier, 2 Itemgroepen, 16 Data-elementen, 2 Talen
Itemgroepen: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00518895

Melanoma Concomitant Medication NCT00110019 - Concomitant Medication Melanoma NCT00110019 E2603 No. 2169

- 26-03-15 - 1 Formulier, 2 Itemgroepen, 29 Data-elementen, 2 Talen
Itemgroepen: Header, Concomitant Medication
E2603 Concomitant Medication Form Form No. 2169 Carboplatin and Paclitaxel With or Without Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Melanoma NCT00110019 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=E7D649ED-D8C9-54BD-E034-0003BA3F9857

Eligibility NCT00395070 Metastatic Melanoma - Eligibility

- 15-04-14 - 1 Formulier, 2 Itemgroepen, 11 Data-elementen, 2 Talen
Itemgroepen: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00395070

Eligibility NCT01355120 Advanced Ocular Melanoma - Eligibility

- 20-09-21 - 1 Formulier, 2 Itemgroepen, 35 Data-elementen, 2 Talen
Itemgroepen: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT01355120

Melanoma Eligibility Interferon Alpha NCT00226408 - Eligibility Melanoma NCT00226408

- 06-06-15 - 1 Formulier, 3 Itemgroepen, 45 Data-elementen, 2 Talen
Itemgroepen: Inclusion Criteria, Exclusion Criteria, Medical concepts
Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon ODM derived from http://clinicaltrials.gov/show/NCT00226408

Melanoma Adverse Event E1609 NCT01274338 - Adverse Event Melanoma (CTCAE v4) - Arm A NCT01274338

- 21-04-15 - 1 Formulier, 5 Itemgroepen, 24 Data-elementen, 1 Taal
Itemgroepen: Header Module, ON TREATMENT, Adverse Event, Adverse event hematologic or metabolic, Other Adverse Events
E1609 Adverse Event Form (CTCAE v4) - Arm A Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery NCT01274338 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=97ED76E3-6554-CD9F-E040-BB89AD430E2E

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial